Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Targeted Therapies

Targeted Therapies and Immunotherapies Approved for Patients with Non–Small-Cell Lung Cancer in 2020-2022
This article highlights the new therapies targeting a specific biomarker that have become available for patients with non–small-cell lung cancer in the past 3 years, significantly improving patient survival. Read More ›

Understanding Personalized Medicine and Genetics in Cancer: Why This Matters to Patients
Sometimes we hear words that sound familiar but we don’t fully know their meaning. This article explains the common terms “personalized medicine” and “targeted therapy” used by oncologists, and why we need to understand them. Read More ›

Exkivity Second FDA-Approved Oral Targeted Therapy for Patients with Metastatic NSCLC and EGFR Exon 20 Insertion Mutations
On September 15, 2021, the FDA approved Exkivity (mobocertinib) capsules, an oral kinase inhibitor, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed during or after platinum-based chemotherapy, a cancer with few treatment options. Read More ›

¹⁷⁷Lu-PSMA-617, Novel Targeted Therapy, Extends Survival in Men with Metastatic Prostate Cancer

New Targeted Therapy for Patients with Metastatic Triple-Negative Breast Cancer
People with triple-negative breast cancer (TNBC) that has spread to other parts of the body (metastatic) now have a new treatment option called Trodelvy (sacituzumab govitecan-hziy). This drug was recently approved by the Food and Drug Administration (FDA) for use specifically in adult patients with metastatic TNBC who have already received at least 2 previous treatments for their cancer. Read More ›

Oncogene Alterations Affect the Response to Targeted Therapies in Patients with Non–Small-Cell Lung Cancer and ALK Rearrangements
One biomarker that is involved in lung cancer is the ALK mutations. Although several drugs are now available for this type of lung cancer, new evidence shows that some patients may need different therapies. Read More ›

Considering the Role of Oral Targeted Therapies in the Treatment of Patients with Leukemia
Just because a cancer drug is approved by the FDA does not mean its therapeutic benefit is completely understood. Improving outcomes and minimizing side effects of a drug often requires using the drug in different doses or in combination with other drugs. Read More ›

Information Is Power: Targeted Therapies Extend Survival for Patients with Chronic Lymphocytic Leukemia
Until recently, the initial treatment for patients with CLL was chemotherapy alone. New targeted therapies are now available for use as the first treatment for CLL. At the 2019 ASCO meeting, 2 experts discussed the benefits of these new treatments. Read More ›

Targeted Therapy Better Than Chemotherapy as First Treatment for Some Patients with Chronic Lymphocytic Leukemia
New findings show that starting with a targeted therapy regimen instead of chemotherapy improves outcomes for patients with chronic lymphocytic leukemia, particularly for those under age 70. Read More ›

Targeted Therapies: Finding the Key to Managing Non–Small-Cell Lung Cancer
Targeted therapies for lung cancer are newer therapies designed to target specific types of genetic mutations found in some patients, and improve the response to treatment. Read More ›